참고문헌
- Bendoraite A, Knouf EC, Garg KS, et al (2010). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-toepithelial transition. Gynecol Oncol, 116, 117-25. https://doi.org/10.1016/j.ygyno.2009.08.009
- Calin GA, Ferracin M, Cimmino A, et al (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 353, 1793-801. https://doi.org/10.1056/NEJMoa050995
- Calin GA and Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66. https://doi.org/10.1038/nrc1997
- Chen J, Wang L, Matyunina LV, et al (2011). Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol, 121, 200-5. https://doi.org/10.1016/j.ygyno.2010.12.339
- Chen Y, Zhang L and Hao Q (2013). Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int, 13, 86. https://doi.org/10.1186/1475-2867-13-86
- Di Leva G and Croce CM (2013). The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol, 3, 153.
- Faragalla H, Youssef YM, Scorilas A, et al (2012). The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn, 14, 385-92. https://doi.org/10.1016/j.jmoldx.2012.02.003
- Flavin RJ, Smyth PC, Finn SP, et al (2008). Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol, 21, 676-84. https://doi.org/10.1038/modpathol.2008.33
- He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31. https://doi.org/10.1038/nrg1379
- Hernando E (2007). microRNAs and cancer: role in tumorigenesis, patient classification and therapy. Clin Transl Oncol, 9, 155-60. https://doi.org/10.1007/s12094-007-0029-0
- Hu X, Macdonald DM, Huettner PC, et al (2009). A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol, 114, 457-64. https://doi.org/10.1016/j.ygyno.2009.05.022
- Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707. https://doi.org/10.1158/0008-5472.CAN-07-1936
- Koberle V, Kronenberger B, Pleli T, et al (2013). Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, 49, 3442-9. https://doi.org/10.1016/j.ejca.2013.06.002
- Korpal M, Lee ES, Hu G and Kang Y (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem, 283, 14910-4. https://doi.org/10.1074/jbc.C800074200
- Kota J, Chivukula RR, O'Donnell KA, et al (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137, 1005-17. https://doi.org/10.1016/j.cell.2009.04.021
- Kumar MS, Erkeland SJ, Pester RE, et al (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA, 105, 3903-8. https://doi.org/10.1073/pnas.0712321105
- Laios A, O'Toole S, Flavin R, et al (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer, 7, 35. https://doi.org/10.1186/1476-4598-7-35
- Landen CN, Jr., Birrer MJ and Sood AK (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol, 26, 995-1005. https://doi.org/10.1200/JCO.2006.07.9970
- Leskela S, Leandro-Garcia LJ, Mendiola M, et al (2011). The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer, 18, 85-95.
- Li Z, Lu J, Sun M, et al (2008). Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA, 105, 15535-40. https://doi.org/10.1073/pnas.0808266105
- Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8. https://doi.org/10.1038/nature03702
- Mateescu B, Batista L, Cardon M, et al (2011). miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med, 17, 1627-35. https://doi.org/10.1038/nm.2512
- Mo MH, Chen L, Fu Y, et al (2012). Cell-free circulating miRNA biomarkers in cancer. J Cancer, 3, 432-48. https://doi.org/10.7150/jca.4919
- Mostert B, Sieuwerts AM, Martens JW and Sleijfer S (2011). Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn, 11, 259-75.
- Nam EJ, Yoon H, Kim SW, et al (2008). MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 14, 2690-5. https://doi.org/10.1158/1078-0432.CCR-07-1731
- Resnick KE, Alder H, Hagan JP, et al (2009). The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 112, 55-9. https://doi.org/10.1016/j.ygyno.2008.08.036
- Shell S, Park SM, Radjabi AR, et al (2007). Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA, 104, 11400-5. https://doi.org/10.1073/pnas.0704372104
- Shen J, Ambrosone CB, DiCioccio RA, et al (2008). A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-6. https://doi.org/10.1093/carcin/bgn172
- Skaftnesmo KO, Prestegarden L, Micklem DR and Lorens JB (2007). MicroRNAs in tumorigenesis. Curr Pharm Biotechnol, 8, 320-5. https://doi.org/10.2174/138920107783018390
- Tang Z, Ow GS, Thiery JP, et al (2013). Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer, 134, 306-18.
- Tavazoie SF, Alarcon C, Oskarsson T, et al (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-52. https://doi.org/10.1038/nature06487
- Taylor DD, Gercel-Taylor C (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 110, 13-21. https://doi.org/10.1016/j.ygyno.2008.04.033
- Trang P, Medina PP, Wiggins JF, et al (2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene, 29, 1580-7. https://doi.org/10.1038/onc.2009.445
- Wong AS and Auersperg N (2003). Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol, 1, 70. https://doi.org/10.1186/1477-7827-1-70
- Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60. https://doi.org/10.1261/rna.1034808
- Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98. https://doi.org/10.1016/j.ccr.2006.01.025
- Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33. https://doi.org/10.1158/0008-5472.CAN-07-2488
- Yang N, Kaur S, Volinia S, et al (2008). MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res, 68, 10307-14. https://doi.org/10.1158/0008-5472.CAN-08-1954
- Zhang L, Volinia S, Bonome T, et al (2008). Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA, 105, 7004-9. https://doi.org/10.1073/pnas.0801615105
피인용 문헌
- Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines vol.12, pp.3, 2016, https://doi.org/10.3892/ol.2016.4831